Dare Bioscience, Inc. Proceeds from Notes Payable
Dare Bioscience, Inc. (DARE) reported Proceeds from Notes Payable of $486.72 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-03-26
- Dare Bioscience, Inc. proceeds from notes payable for the quarter ending 2025-12-31 was $1.00.
- Dare Bioscience, Inc. proceeds from notes payable for the quarter ending 2024-12-31 was $0.00.
- Dare Bioscience, Inc. proceeds from notes payable for the quarter ending 2023-12-31 was $0.00.
- Dare Bioscience, Inc. proceeds from notes payable for the quarter ending 2022-12-31 was $0.00.
- Dare Bioscience, Inc. proceeds from notes payable for fiscal 2025 was $486.72K, a 13.34% decline from fiscal 2024.
- Dare Bioscience, Inc. proceeds from notes payable for fiscal 2024 was $561.66K, a 6.57% decline from fiscal 2023.
- Dare Bioscience, Inc. proceeds from notes payable for fiscal 2023 was $601.17K.
- Dare Bioscience, Inc. proceeds from notes payable for fiscal 2022 was $0.00.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month | Proceeds from Notes Payable 100 month |
|---|---|---|---|---|---|
| 2025-12-31 | $1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $486.72K 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $486.72K 10-Q · filed 2025-11-13 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $561.66K 10-K · filed 2026-03-26 | |||
| 2024-09-30 | $561.66K 10-Q · filed 2025-11-13 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $601.17K 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $601.17K 10-Q · filed 2024-11-14 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $0.00 derived: sum of 2 quarters · filed 2022-03-31 | $0.00 10-K · filed 2022-03-31 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $0.00 derived: sum of 2 quarters · filed 2022-03-31 | $367.29K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $367.29K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $367.29K 10-Q · filed 2021-08-12 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $0.00 derived: sum of 2 quarters · filed 2021-03-30 | $0.00 10-K · filed 2021-03-30 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | ||||
| 2015-12-31 | $6.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-06-13 | $6.00M derived: sum of 2 quarters · filed 2017-06-13 | $6.00M derived: sum of 3 quarters · filed 2017-06-13 | $21.00M 10-K/A · filed 2017-06-13 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $0.00 derived: sum of 2 quarters · filed 2016-11-03 | $15.00M 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $15.00M 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | $15.00M 10-Q · filed 2016-05-02 | ||||
| 2014-03-31 | $10.70M 10-Q · filed 2014-05-27 | ||||
| 2012-12-31 | $10.00M 10-K · filed 2015-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |